Navigation Links
Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,,and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology -

NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from a Phase II study - which will be published in the August 10, 2007 issue of the Journal of Clinical Oncology (JCO) and are now available as an Early Release Article at www.jco.org - demonstrate that ixabepilone, a Bristol-Myers Squibb Company investigational compound, has activity in patients with metastatic breast cancer whose tumors were resistant to three types of standard chemotherapy (anthracycline, taxane, and capecitabine). Currently, there are few proven treatment options available to patients with breast cancer whose disease has rapidly progressed through or whose disease is not responding to prior treatment with approved chemotherapies. This study was one of five Phase II ixabepilone studies published in this issue of JCO, including three additional studies in metastatic breast cancer and one in non-small cell lung cancer.

"Drug resistance is a major concern in treating patients with advanced disease," said Renzo Canetta, vice president, Oncology Global Clinical Research, Bristol-Myers Squibb. "The results of this study are important as they provide valuable information about this investigational compound and its potential in patients with advanced breast cancer that is no longer responding to any of the current U.S. approved chemotherapy treatments."

The 126 patients enrolled in the single-arm Phase II study (CA163081) had heavily pretreated, advanced metastatic breast cancer, which had progressed through three prior therapies (anthracycline, taxane and capecitabine). The primary endpoint was objective response rate, which is an assessment of the response to treatment as determined by the independent radiology facility (IRF). Secondary efficacy endpoints included duration of response, time to response, progres
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/2/2015)... , June 25, 2015 ... of the "Veterinary / Animal Vaccines Market by ... report to their offering. The global ... by 2020 from $5,507.3 Million in 2015, at a ... Major factors fueling market growth are growing prevalence of ...
(Date:7/2/2015)... Agreement reinforces ...   ViiV Healthcare and Desano Pharmaceuticals (Desano) ... China of dolutegravir. The agreement will ... (API), and will allow ViiV Healthcare to offer a competitive ... name Tivicay®) for China and a ...
(Date:7/1/2015)... Colo. , July 1, 2015   ... in implantable hearing solutions, announced today the US ... Cochlear™ Nucleus® Profile™ Implant with Slim Straight Electrode ... and developed in close collaboration with the world,s ... cochlear implant platform designed to provide the most ...
Breaking Medicine Technology:Veterinary / Animal Vaccines Market 2015 - Global Forecast to 2020 for the $7.19 Billion Industry 2ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 2ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 3ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 4ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 5ViiV Healthcare and Desano Pharmaceuticals' Manufacturing Agreement Will Allow Competitive Supply of Dolutegravir in China and Several Developing Countries 6Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 2Cochlear Combines the World's Thinnest Cochlear Implant Platform with the Industry's Thinnest Full Length Electrode 3
(Date:7/2/2015)... Pennsylvania (PRWEB) , ... July ... ... largest e-commerce janitorial supply company , announced today that it has ... Products. The acquisition will make CleanItSupply.com the largest distributor of Rubbermaid Commercial ...
(Date:7/2/2015)... ... July 02, 2015 , ... Breakthrough technologies ... pain treatment. Dr. Lev Kalika, founder of New York Dynamic Neuromuscular Rehabilitation ... on the conservative treatment of back, hip, knee and shoulder pain as well ...
(Date:7/2/2015)... ... July 02, 2015 , ... Five ... Preparedness (CDP) in Anniston for specialized disaster training. The team – composed of ... the Southern California Hospital Association who attended the training, which is dedicated to ...
(Date:7/2/2015)... ... July 02, 2015 , ... B. E. ... been retained to lead a national chief executive officer recruitment for ... in the healthcare industry, B. E. Smith has recently placed more than 1,000 ...
(Date:7/2/2015)... AR (PRWEB) , ... July 02, 2015 , ... Throughout ... families through their annual “Dog Tag” campaign. On Tuesday, July 7, Casey’s General ... Warriors® for nearly $800,000. Hope For The Warriors® is a national nonprofit dedicated to ...
Breaking Medicine News(10 mins):Health News:CleanItSupply.com Acquires eRubbermaid.com 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 2Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 3Health News:Breakthrough Technologies for Carpal Tunnel Treatment in New York City 4Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 2Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 3Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 2Health News:Indiana Blood Center Retains B. E. Smith to Recruit New Chief Executive Officer 3Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 2Health News:Casey’s General Stores to Present Donation from “Dog Tag” Campaign to Hope For The Warriors® 3
... of effectiveness over time , , MONDAY, May 12 (HealthDay News) ... legs syndrome do provide relief, but they are burdened by ... many sufferers to stop taking them, a new analysis finds. ... can,t fully explain is that they have more robust effects ...
... baby boomers say,they are financially unprepared for a ... Harris Interactive on behalf of America,s Health,Insurance Plans ... and,many would have to tap into their retirement ... ), "Baby boomers have too much ...
... assessments worldwide verify safety and quality of technically ... advanced zirconium oxide material., ... provider of,ceramic solutions for the medical device industry, has submitted ... (FDA) for,its new technical ceramic dental component, ZirDent(TM) CAD/CAM Blocks.,ZirDent(TM) ...
... CHENGDU, China, May 12 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, Co., ... of modernized traditional Chinese medicine ("TCM") based in,Chengdu, ... at Roth Third,Annual China Discovery Tour on Tuesday, ... Conference will be held at the Regent Hotel ...
... trial in bladder cancer exceeds 2/3rds enrolment level ... pre-clinical work in peritoneal cancers -, BELLEVILLE, ... (TSX: BNC), a research-based, technology-driven Canadian,biopharmaceutical company, is ... non-clinical development of its proprietary platform technology:,Mycobacterial Cell ...
... Re-implantation of devices at shorter distances improved motor scores, ... A few millimeters can make a huge difference for ... brain, a new study finds. , Implanting electrodes ... brain potentially related to impulsivity, has helped people with ...
Cached Medicine News:Health News:Drugs for Restless Legs Syndrome Have Downsides 2Health News:Drugs for Restless Legs Syndrome Have Downsides 3Health News:Most Baby Boomers are Financially Unprepared for a Potential Disability 2Health News:C5 Medical Werks Applies for Clearance, Certification and Licensing for the Global Marketing of ZirDent(TM) Ceramic CAD/CAM Dental Blocks 2Health News:Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time 2Health News:Bioniche Updates re: Mycobacterial Cell Wall Technology Platform 2Health News:Bioniche Updates re: Mycobacterial Cell Wall Technology Platform 3Health News:Bioniche Updates re: Mycobacterial Cell Wall Technology Platform 4Health News:Electrode Placement Key to Brain Stimulation for Parkinson's Patients 2
Used for access and catheterization procedures. Double flexible tipped design permits alternative use of both ends of wire guide depending upon procedural needs. Supplied sterile in peel-open package...
Used for complex diagnostic and interventional procedures....
The Emerald Guidewire is intended for percutaneous introduction of catheters....
... Medical offers a complete line ... with percutaneous catheter introducers to ... catheters. Our diagnostic guidewires are ... incorporate a proprietary surface finish ...
Medicine Products: